http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112239469-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0821 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06034 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-103 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-097 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-062 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2020-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112239469-B |
| titleOfInvention | Targeted protein degradation c-Met degradation agent and preparation method and application thereof |
| abstract | The invention discloses a targeted protein degradation c-Met degradation agent, and a preparation method and application thereof. The invention provides a c-Met degradation agent based on a PROTAC (protein targeted degradation) strategy, a preparation method thereof and application of the c-Met degradation agent in treating cancers such as non-small cell lung cancer, gastric cancer and the like. The compound has obvious c-Met degradation effect and cell proliferation inhibition effect, has the potential of being used as an anti-tumor drug for treating tumors, shows obvious proliferation inhibition activity in EBC-1 drug-resistant cell strains constructed by lentivirus transfection, is obviously superior to a small molecule inhibitor LXM-262, and obviously improves cell selectivity, thereby indicating that the compound of the embodiment of the invention has obvious advantages in overcoming the acquired drug resistance of the tumors, particularly the compound S27 shows better activity only on the EBC-1 lung cancer cells dependent on the c-Met, indicating that the compound S27 has better cell selectivity, while the original small molecule inhibitor is multi-target and has inhibition effect on the cell lines independent on the c-Met. |
| priorityDate | 2020-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 132.